Harrow announced an expansion of its Vevye Access for All program to include patients currently prescribed Klarity-C Drops, a compounded cyclosporine 0.1% product manufactured and distributed by ImprimisRx, Harrow’s compounding subsidiary.

Beginning immediately, more than 25,000 patients across the United States will be able to convert their Klarity-C prescriptions to Vevye (cyclosporine ophthalmic solution) 0.1%, an FDA‑approved treatment for the signs and symptoms of dry eye disease, for $59 per bottle (including refills). As a part of this transition, Klarity-C prescribers have access to a prescription authorization platform to transfer Klarity-C prescriptions to PhilRx in a process that shouldn’t take more than 5 minutes, according to the company.